Socorro España Lomelí, executive director of Mexico’s National Association of Drug Manufacturers (ANAFAM), details her strategic priorities with regards to the promotion of the industry’s export strategy, the implementation of world-class manufacturing norms, the development of biosimilars and API manufacturing, as well as recognizing the pharmaceutical sector as a strategic industry for Mexico’s economy and population.
In June 2016, ANAFAM organized the fifth edition of Vector Pharma, which has been rapidly increasing its line-up to gather up to 80 companies from 27 countries around the globe in 2016, and managed key international experts for its main seminar. How do you explain this overwhelming success?
The international business community is clearly interested in developing commercial relationships with Mexican drug manufacturers.
